Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma

European Journal of Cancer

Volumn 41, Issue 9, 2005, Pages 1349-1361

  Scotlandi, Katia ^a   Manara, Maria C ^a   Hattinger, Claudia M ^a   Benini, Stefania ^a   Perdichizzi, Stefania ^a   Pasello, Michela ^a   Bacci, Gaetano ^a   Zanella, Licciana ^a   Bertoni, Franco ^a   Picci, Piero ^a   Serra, Massimo ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Ewing's sarcoma; HER2; IGF IR; Osteosarcoma; P glycoprotein; Trastuzumab

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN P; METHOTREXATE; PARAFFIN; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TUMOR BIOPSY; TUMOR RECURRENCE;

EID: 20444501794     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.015     Document Type: Article

References (48)

1. L. Coussens, T.L. Yang-Feng, and Y.C. Liao Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1985 1132 1139
2. C.R. King, M.H. Kraus, and S.A. Aaronson Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 1985 974 976
3. T. Akiyama, C. Sudo, and H. Ogawara The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1986 1644 1656
4. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
5. N.E. Hynes, and D.F. Stern The biology of erbB-2/neu/HER-2 and its role in cancer Biochim Biophys Acta 1198 1994 165 184
6. D. Yu, J.K. Wolf, and M. Scanlon Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A Cancer Res 53 1993 891 898
7. D. Yu, S.S. Wang, and K.M. Dulski c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties Cancer Res 54 1994 3260 3266
8. C.M. Tsai, D. Yu, and K.T. Chang Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells J Natl Cancer Inst 87 1995 682 684
9. D. Yu, B. Liu, and M. Tan Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms Oncogene 13 1996 1359 1365
10. O. Merimsky, J. Issakov, and I. Schwartz Lack of ErbB-2 oncogene product overexpression in soft tissue sarcomas Acta Oncol 41 2002 366 368
11. H. Foster, S. Knox, and A.K. Ganti HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas Am J Clin Oncol 26 2003 188 191
12. T. Sato, M. Peiper, and A. Heinecke Expression of HER2/neu does not correlate with survival in soft tissue sarcoma Onkologie 26 2003 268 271
13. D.G. Thomas, T.J. Giordano, and D. Sanders Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma Clin Cancer Res 8 2002 788 893
14. E. George, G.A. Niehans, and P.E. Swanson Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumours of childhood. An immunohistochemical investigation Arch Pathol Lab Med 116 1992 1033 1035
15. M. Onda, S. Matsuda, and S. Higaki ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma Cancer 77 1996 71 78
16. R. Gorlick, A.G. Huvos, and G. Heller Expression of HER2/erbB-2 correlates with survival in osteosarcoma J Clin Oncol 17 1999 2781 2788
17. S.E. Kilpatrick, K.R. Geisinger, and T.S. King Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma Mod Pathol 14 2001 1277 1283
18. T. Akatsuka, T. Wada, and Y. Kokai ErbB2 expression is correlated with increased survival of patients with osteosarcoma Cancer 94 2002 1397 1404
19. A. Maitra, D. Wanzer, and A.G. Weinberg Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas Cancer 92 2001 677 683
20. H. Zhou, R.L. Randall, and A.R. Brothman Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification J Pediatr Hematol Oncol 25 2003 27 32
21. J.K. Anninga, M.J. van de Vijver, and A.M. Cleton-Jansen Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas Eur J Cancer 40 2004 963 970
22. Z. Zhou, S.F. Jia, and M.C. Hung E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs Cancer Res 61 2001 3394 3398
23. D. Ye, A. Maitra, and C.F. Timmons The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma J Pediatr Hematol Oncol 25 2003 459 466
24. N. Baldini, K. Scotlandi, and G. Barbanti-Bròdano Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome New Eng J Med 333 1995 1380 1385
25. H.S. Chan, T.M. Grogan, and G. Haddad P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy J Natl Cancer Inst 89 1997 1706 1715
26. E.E. Pakos, and J.P. Ioannidis The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis Cancer 98 2003 581 589
27. M. Serra, K. Scotlandi, and G. Reverter-Branchat Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities J Clin Oncol 21 2003 536 542
28. G. Bacci, S. Ferrari, and F. Bertoni Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli J Clin Oncol 18 2000 4 11
29. P. Picci, B.T. Rougraff, and G. Bacci Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities J Clin Oncol 11 1993 1763 1769
30. S. Ferrari, F. Bertoni, and M. Mercuri Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 303 patients treated at the Rizzoli Institute Ann Oncol 12 2001 1145 1150
31. P. Bieling, N. Rehan, and P. Winkler Tumour size and prognosis in aggressively treated osteosarcoma J Clin Oncol 14 1996 848 858
32. S. Benini, N. Baldini, and M.C. Manara Redundancy of autocrine loops in human osteosarcoma cells Int J Cancer 80 1999 581 588
33. K. Scotlandi, M.C. Manara, and R. Strammiello C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions J Clin Oncol 21 2003 1952 1960
34. K. Scotlandi, S. Avnet, and S. Benini Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumourigenesis and enhances chemosensitivity in Ewing's sarcoma cells Int J Cancer 101 2002 11 16
35. K. Scotlandi, C. Maini, and M.C. Manara Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells Cancer Gene Ther 9 2002 296 307
36. D.P.M. Hughes, D.G. Thomas, and T.J. Giordano Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma Cancer Res 64 2004 2047 2053
37. M.A. Cobleigh, C.L. Vogel, and D. Tripathy Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648
38. S. Menard, S.M. Pupa, and M. Campiglio Biologic and therapeutic role of HER2 in cancer Oncogene 22 2003 6570 6578
39. Y. Lu, X. Zi, and Y. Zhao Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 2001 1852 1857
40. Y. Lu, X. Zi, and M. Pollak Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells Int J Cancer 108 2004 334 341
41. K. Scotlandi, S. Benini, and P. Nanni Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice Cancer Res 58 1998 4127 4131
42. M.F. Press, G. Hung, and W. Godolphin Cancer Res 54 1994 2771 2777
43. H.S. Chan, and V. Ling Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: diagnostic and clinical implications J Natl Cancer Inst 89 1997 1473 1476
44. A. Roessner, Y. Ueda, and B. Bockhorn-Dworniczak Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma J Cancer Res Clin Oncol 119 1993 185 189
45. Y.M. Hijazi, C.A. Axiotis, and S. Navarro Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumours before and after chemotherapy Am J Clin Pathol 102 1994 61 67
46. T. Perri, M. Fogel, and S. Mor Effect of P-glycoprotein expression on outcome in the Ewing family of tumours Pediatr Hematol Oncol 18 2001 325 334
47. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl J Med 344 2001 783 792
48. M. Piccart Closing remarks and treatment guidelines Eur J Cancer 37 2001 S30 S33